Compositions of Essentially Pure Form IV of N-((R)-2,3-Dihydroxypropoxy)-3,4-Difluoro-2-(2-Fluoro-4-IODO-PHENYLAMINO)-BENZAMIDE and Uses Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 17/178,022, filed Feb 17, 2021. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,066,358 | Compositions of Essentially Pure Form IV of N-((R)-2,3-Dihydroxypropoxy)-3,4-Difluoro-2-(2-Fluoro-4-IODO-PHENYLAMINO)-BENZAMIDE and Uses Thereof In force · High confidence UsedRemaining | Warner-Lambert Company LLC | In force | High confidence | ||
| US 11,453,641 | Methods of Treating Neurofibromatosis with N-((R)-2,3-Dihydroxypropoxy)-3,4-Difluoro-2-(2-Fluoro-4-Iodophenylamino)-BENZAMIDE In force · Medium confidence | Warner-Lambert Company LLC | In force | Medium confidence | ||
| US 12,037,306 | Methods of Treating Neurofibromatosis Type 1 with N-((R))-2,3-Dihydroxypropoxy)-3,4-Difluoro-2-(2-Fluoro-4-Iodophenylamino)-BENZAMIDE In force · Medium confidence | Warner-Lambert Company LLC | In force | Medium confidence | ||
| Application 18/762,247 | Compositions of Essentially Pure Form IV of N-((R)-2,3-Dihydroxypropoxy)-3,4-Difluoro-2-(2-Fluoro-4-IODO-PHENYLAMINO)-BENZAMIDE and Uses Thereof Pending Not granted | Warner-Lambert Company LLC | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Warner-Lambert Company LLC.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.